1、UpToDate について *2022年1月時点の情報を基にしています。

UpToDateとは、各分野の世界中の専門医で構成される執筆陣が、自身の臨床経験と最新文献の臨床情報を統合し、 エビデンスに基づく最善の診療指針をまとめた、臨床意思決定支援ツールです。

入手し得る最良のエビデンスに基づいたグローバルスタンダードの情報が日々の診療を支援し、情報収集にかける時間 を短縮します。個別疾患の基礎知識・背景から、詳細な治療方法まで、包括的かつ実用的な情報が得られる為、熟練医から 研修医、薬剤師、看護師に至るまで、幅広く医療従事者の皆様に活用されています。

世界 38,800 以上の施設、191 か国以上で採用され、200 万人を超える方々 が UpToDate を利用しています。日本でも既に 750 以上の施設でご導入いただ いております。採用施設では、患者ケア、合併症、死亡率、教育効果などに統計的な 有意性があることが、研究で報告されています。



(概要動画は <u>https://bit.ly/3eXieQN</u> か 右の QR コードから)

臨床現場の疑問解決・EBMの実践のほか、プレゼンテーション資料を簡単に作成できる機能、薬物相互作用を調べるツール、論文執筆の際に有用な機能が揃っていますので、是非ご活用下さい。



契約施設内からのアクセス方法:

インターネット閲覧可能な PC のブラウザを開き「<u>https://www.uptodate.com/contents/search</u>」に アクセスして下さい。(お客様によって、接続環境が異なる場合がございます。)

契約施設外からのアクセス方法(UpToDate Anywhere のお客様限定):

重要:予めアカウント登録(無料)を行い、ログイン用の Username と Password を設定頂く必要があります。アカウント登録について、本紙の「アカウント登録(p18)」か、別紙の「登録ガイド(公式資料)」をご覧下さい。

- 1. PC のブラウザを開き「<u>https://www.uptodate.com/login</u>」にアクセスすると、以下の画面が表示されます。
- 2. 登録した Username と Password でログインして頂けます。

UpToDate °	UpTo	Dateを検索する	٩	日本語 ~
UpToDate を選ぶ理由	製品	編集 購読オプション		
		Log in Username		
		Password	© Show	
		Remember me	Forgot username or password	
			Log In	
		Log in using you OpenAthens Shibbol	Ir institution leth More Options	

2、UpToDate 利用クイックガイド

臨床上の疑問を検索します

Home 画面にある検索ボックスに検索ワードを入力して、 をクリックします。
 (病名、症状、薬品・薬剤名、手技名、検査用語、略語など、様々なキーワードに対応しています。複数語を入れる場合は、その間にスペースを入れてください。日本語で検索できますが、コンテンツは英語で表示されます。)

UpToDateを検索する	
胃がん	× Q



*スマホアプリでは

2. 検索結果画面の上部には、以下のフィルターが付いており、それぞれをクリックすることで検索結果を更に絞り込むこ とが可能です。選択されているフィルターには下線が入っています。初期設定では「全てのトピック」が選択されており UpToDate の全コンテンツの中から検索結果が表示されます。



3. これらのフィルターの下には、入力したキーワードに関連性が高い順にコンテンツのタイトルが表示されます。各タイト ルの上にマウスポインタを合わせると ご が表示され、そこにポインターを当てると、Topic Outline や関連画像 への直接リンクが表示され、内容を素早く把握することができます。



また、画面右上の「結果を展開する」をクリックすると、下図のように

各トピックにてよく閲覧されている項目が表示されます。

く 戻る	全てのトピック	成人	小児	患者向け	画像	結果を折りたたむ
胃がん に関連	重する検索結果を表示し	しています				クリックごとに切り替わります
胃癌の臨床	転り特徴、診断、おる	よび 病期分	類			結果を展開する
	gastric cancer accour ancer and comprises diffuse gastric cance					
Signs and	d symptoms			7		
Additiona	al tests in selected pat	tients		-		
Summary	y and recommendatio	ons				
🔢 Stoma	ach cancer TNM, 8th e	edition		補足	「結果を展開	開する」をクリックすると、各トピックにて
ぷ Algori	ithmic approach to ga	astric cance	r staging	よく閲	覧されてし	いる Outline や画像が表示されます

4. ここでは上記の「胃癌の臨床的特徴、診断、および病気分類」をクリックしてみます。タイトルをクリックすると、トピック が開きます。 これらの文章トピックは 12,000 以上あり、全て同じレイアウトになっています。

C 展る 「 て pic Outline 「 C linical features, diagnosis, and staging 「 gastric cancer 」 Clinical features, diagnosis, and staging 「 gastric cancer 」 Attor: Paul E Mansfield.MD.EACS Section Editor:: Kenneth K Tanabe.MD.Jon Thus figing and symptoms Paraneoplastic manifestations Paraneoplastic manifestations Toticolosures All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan 2021. This topic last updated: Feb 01, 2021. A fallo Ka@gastric cancer in the United States are Symptomatic and already have advanced, incurable disease at the time of presentation. Despit So percent have disease that time of presentation. Despit So percent have diseases that time of presentation. Despit Symp	<mark>左側</mark> Outline(見出し): クリックするとその項目までジャンプします	<mark>右側</mark> 本文: 臨床現場で役に立つコンテンツがコンパクトにまとまっています
Topic Outline SUMMARY AND RECOMMENDATIONS Author: Paul F Mansfield, MD, FACS INTRODUCTION gastric cancer タイトル INTRODUCTION Deputy Editors: Diane ME Savarese, MD, Shi 執筆陣・編集陣: クリックすると 所属や専門などが表示されます Signs and symptoms Paraneoplastic manifestations Deputy Editors: Diane ME Savarese, MD, Shi 執筆陣・編集陣: クリックすると 所属や専門などが表示されます IMAGING FINDINGS Contributor Disclosures All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan 2021. This topic last updated: Feb 01, 2021. DIAGNOSIS ↑ 右側が最終要新日、左側が関連する主要ジャーナルの確認月です *更新日から時間が経過していても、左側の確認月で最新情報が加味さ れていることを確認することができます Staging systems * TNM staging criteria . * Treatment implications of clinical staging Evaluation * Suggested approach . * Suggested approach Suggested approach .	く戻る	gastric cancer 検索 🥝 🗟 😪 🗚 🖓
SUMMARY AND RECOMMENDATIONS Of gastric cancer タイトル INTRODUCTION Author: Paul F Mansfield, MD, FACS Section Editors: Kenneth K Tanabe, MD, Jon Deputy Editors: Diane MF Savarese, MD, Shi Revemptodiate 執筆陣・編集陣:クリックすると 所属や専門などが表示されます CLINICAL FEATURES Signs and symptoms All topics are updated as new evidence becomes available and our peer review process is complete. MAGING FINDINGS Cross-sectional imaging All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan 2021.] This topic last updated: Feb 01, 2021. DIAGNOSIS A fallが最終更新日、左側が関連する主要ジャーナルの確認月です *更新日から時間が経過していても、左側の確認月で最新情報が加味されていることを確認することができます Most patients with gastric cancer in the United States are symptomatic and already have advanced, incurable disease at the time of presentation. Despit 50 percent have disease that at the time of presentation. Despit 50 percent have disease that at the time of presentation. Despit 50 percent have disease that at the time of presentation. Autor State are symptomatic and already have advanced, incurable disease at the time of presentation. Despit 50 percent have disease that at the time of presentation. Despit 50 percent have disease that at the time of presentation. Despit 50 percent have disease that at the time of presentation. Autor State are symptomatic and are onty intergeneration are day at a control attraction outputs of a day action are and a traction outputs of a day action are and a traction outputs of a day action are and a traction outputs of a day action are an action. Surgicially StaGING EVALUATION Suggested approach Suggested approa	Topic Outline	Clinical features, diagnosis, and staging
INTRODUCTION Author: Paul F Mansfield, MD, FACS 熱筆陣・編集陣: クリックすると Section Editors: Kenneth K Tanabe, MD, Jon 執筆陣・編集陣: クリックすると Deputy Editors: Diane MF Savarese, MD, Sh 新筆陣・編集陣: クリックすると Signs and symptoms Deputy Editors: Diane MF Savarese, MD, Sh 新筆陣・編集陣: クリックすると Paraneoplastic manifestations Contributor Disclosures All topics are updated as new evidence becomes available and our peer review process is complete. IMAGING FINDINGS Literature review current through: Jan 2021. This topic last updated: Feb 01, 2021. Cross-sectional imaging 2021. Barium studies 1 右側が最終更新日、左側が関連する主要ジャーナルの確認月です Upper endoscopy with biopsy Most patients with gastric cancer in the United States are symptomatic and already have advanced, incurable disease at the time of presentation. Despit STAGING EVALUATION So percent have disease that time of presentation. Despit * Treatment implications of clinical staging So percent have disease that at the time of presentation. Despit * Treatment implications of clinical staging at the time of presentation. To have locoregional turori to have locoregional turori to and accenture regulated disease at the urative resection. Surgically * Suggested approach Uservertorestic and accenture resection. Surgically	SUMMARY AND RECOMMENDATIONS	of gastric cancer タイトル
CLINICAL FEATURES Contributor Disclosures Signs and symptoms Contributor Disclosures Paraneoplastic manifestations All topics are updated as new evidence becomes available and our peer review process is complete. IMAGING FINDINGS Literature review current through: Jan 2021. This topic last updated: Feb 01, 2021. Barium studies 	INTRODUCTION	Author: <u>Paul F Mansfield, MD, FACS</u> Section Editors: <u>Kenneth K Tanabe, MD</u> , Jon Deputy Editors: Diane MF Savarese, MD, Sh 所属や専門などが表示されます
IMAGING FINDINGS Literature review current through: Jan 2021. This topic last updated: Feb 01, 2021. Barium studies Adlyn 最終更新日、左側が関連する主要ジャーナルの確認月です *更新日から時間が経過していても、左側の確認月で最新情報が加味されていることを確認することができます Most patients with gastric cancer in the United States are symptomatic and already have advanced, incurable disease at the time of presentation. Despite TNM staging criteria Treatment implications of clinical staging Suggested approach You can be	CLINICAL FEATURES Signs and symptoms Paraneoplastic manifestations	Contributor Disclosures All topics are updated as new evidence becomes available and our <u>peer review</u>
DIAGNOSIS *更新日から時間が経過していても、左側の確認月で最新情報が加味されていることを確認することができます Upper endoscopy with biopsy Most patients with gastric cancer in the United States are symptomatic and already have advanced, incurable disease at the time of presentation. Despite 50 percent have disease that at the time of presentation, a treatment implications of clinical staging →右側の青いタブの「トピックフィー ドバック」は、トピックに対する疑問・ びつうし、トピックに対する疑問・ びつうし、トピックに対する疑問・ てurative resection. Surgically →右側の青いタブの「トピックフィー ドバック」は、トピックに対する疑問・ びつうこの目編集長に該当する方から 24-48 時間以内に返信がきます • Suggested approach Suggested approach Suggested approach	IMAGING FINDINGS Cross-sectional imaging Barium studies	process is complete. Literature review current through: Jan 2021. This topic last updated: Feb 01, 2021. ↑ 右側が最終更新日、左側が関連する主要ジャーナルの確認月です
Most patients with gastric cancer in the United States are STAGING EVALUATION Staging systems • TNM staging criteria • Treatment implications of clinical staging Evaluation • Suggested approach Most patients with gastric cancer in the United States are symptomatic and already have advanced, incurable disease at the time of presentation. Despite o TRM staging criteria at the time of presentation, at the time of pre	DIAGNOSIS	*更新日から時間が経過していても、左側の確認月で最新情報が加味されていることを確認することができます
Staging systems time of presentation. Despite • TNM staging criteria 50 percent have disease that • Treatment implications of clinical staging at the time of presentation, a Evaluation to have locoregional tumor in • Suggested approach usually asymptomatic and are only uptrequently detected outside ot	STAGING EVALUATION	Most patients with gastric cancer in the United States are symptomatic and already have advanced, incurable disease at the
usually asymptomatic and are only innequently detected outside of	Staging systems • TNM staging criteria • Treatment implications of clinical staging Evaluation • Suggested approach	time of presentation. Despite 50 percent have disease that at the time of presentation, a to have locoregional tumor in curative resection. Surgically usually asymptomatic and are only infrequently detected outside of



5. 画面左上の Summary & Recommendations をクリックすると、トピックの要約をご覧いただくと、内容を素早く把握できます。ここには GRADE システムを用いて格付けされた推奨治療法が追記されている場合がございます。 併せて現場での意思決定にお役立て下さい。

Topic Outline	• For patients with dMMR/MSI-H tumors, most of whom have high levels of PD-L1 overexpression, we suggest <u>nivolumab</u> plus chemotherapy rather than chemotherapy alone
SUMMARY AND RECOMMENDATIONS	(Grade 2C). embrolizumab monotherapy is another option. (See <u>'Deficient mismatch repair'</u> above.)
参考:Summaryのみ等 トピックにより異なります	• When combined immunotherapy and chemotherapy is used, the optimal chemotherapy backbone is not established. For most patients, we prefer an oxaliplatin-based regimen such as FOLFOX (Intersection 1), regardless of the specific immune checkpoint inhibitor. (See <u>'Selection</u>
RISK OF CANCER IN CARRIERS OF A PATHOGENIC OR LIKELY PATHOGENIC	<u>of the chemotherapy backbone'</u> above.)
VARIANT	• The benefits of immunotherapy for adenocarcinomas with low-level or no expression of PD-
	L1 remain uncertain. Although opinion differs, especially with regard to CPS 1 to 4, we suggest initial cytotoxic chemotherapy rather than immunotherapy in these patients, unless they have dMMR/MSI-H tumors (Grade 2C). (See <u>'Patients unselected for biomarkers'</u> above.)

Grade についての詳細は以下のサイト(英語)をご参照下さい。 <u>https://www.uptodate.com/ja/home/grading-guide</u>

3、画像検索とパワーポイントへの貼付け

学会発表、講義、各種会議用のプレゼンテーション用資料を簡単に作成

UpToDate には 36,000 を超える画像(図、表、アルゴリズム、イラスト、写真など)や動画があり、画像を PowerPoint のスライドとして出力する機能があります。 各臨床トピックにも多くの画像リンクが付いています。ここで は Home 画面からの画像検索を紹介します。

1. Home 画面の検索ページにて、キーワードを入力します。

UpToDa	te®		
コンテンツ ~	計算ツール	薬物相互作用	
Up	ToDateを検索す	する	
Л	柿炎 治療	×	Q

2. 検索結果画面が表示されます。上部フィルターから、「画像」を選択します。

	治療	XQ	
コンテンツ > 計算ツール	薬物相互作用	UpToDate Pathways	
く 戻る 全てのトピック	成人 小児	患者向け 画像	結果を展開する
肺炎 治療に関連する検索結果を表	気いています		
成人の外来患者における市中肺	「炎の治療		
成人の院内肺炎および人工呼吸 治療	込器関連肺炎の		
入院を要する成人における市中	叩肺炎の治療		
小児における市中肺炎:外来流	遼		

3. 検索ワードに関連する画像が表示されます。PowerPointに出力したい画像をクリックします。



4. 拡大版が表示されますので、ウィンドウの左上にある「Export to PowerPoint」をクリックします。

	Export to PowerPoint	全て表示	フィードバック	ロ ブックマーク	APPEARS IN TOPICS:	
evalt. dehyt n adt	© 2021 UpToDate, Inc. and/or its a Sputum from a patient	affiliates. All Right t with pneu	s Reserved. mococcal pneum	補足:ブック すぐに確認て	マークを使うと、今後、Home 画面か できます(詳細は p17)	15
	Gram stain of sputum (x1000) positive diplococci; Streptococc specimen by culture and by th Courtesy of Harriet Provine. Grambic 75924 Version 5.0	show abun sus pneumariae e optochin dh	Minimatory cells the sector of the sector of	ano tram-	 Sputum cultures for the evaluation of bacterial pneumonia Approach to Gram stain and culture results in the microbiology laboratory 	
		of	Historiasmeic in th	And provide the second se	Terrer handlift	

5. PowerPoint のスライドとしてダウンロードできます。

原則として、UpToDateの画像は、出典付きの状態で、アカデミック目的(院内・学内の勉強会や授業、医学学会、市 民・患者向け説明会等)のプレゼン資料としてご利用いただけますが、ネットなどで公に公開したり、出版されるものの 場合には、許可が必要になります。詳細な要件に関しては、直前の「4」番の画面にある各画像の「フィードバック」ボタ ンから編集部にお問い合わせ下さい。



4、薬物相互作用を調べることができます。

薬を処方する際など、医薬品や薬草間の相互作用を素早く確認できます。(姉妹製品 Lexicomp と提携) ※UpToDate 内の薬剤情報は、UpToDate の姉妹製品である Lexicomp から提供を受けています。UpToDate 上 で見られる Lexicomp の薬剤情報は、FDA 基準になりますので、予めご了承ください。

1. 画面左上の「薬物相互作用」リンクをクリックします。

UpToDa	te°	
コンテンツ 、	計算ツール	薬物相互作用

2. Lexicompの説明や、免責事項をご確認いただき、「Continue」をクリックします。

Welco	ome to Drug Interactions: A Drug-Drug, Drug-Herb, and Herb-Herb analysis tool, provided by UpToDate utilizing Lexicomp clinical content.
Lexi-Inte	eract Online combines interature and scientific understanding of drug interactions throughout the world
with a sl	tate-of-the-art electronic platform, providing an efficient way to help inform healthcare professionals
about a	dverse drug events that otherwise can compromise the care of patients.
Review	all interactions for a selected medication or enter a patient specific regimen to analyze for potential
interacti	ons. Additionally, you may select a drug interaction result to obtain specific information on Patient
Manage	ment, Interacting Members, Risk Rating, References and more.
Disclair	ner: UpToDate publishes summary drug information in this reference resource for use by healthcare
professi	onals in the course of their professional practice. The content in this resource is intended only to
supplem	sent - not substitute for or replace - the knowledge and judgment of physicians, nurses, pharmacists
and othe	rehealthcare professionals regarding drug therapy and patient-specific health conditions.
The con	tent is published based upon publicly available sources generally viewed as reliable in the healthcare
commun	inty, including specifically pharmaceutical manufacturer labeling, information published by regulatory
agencie	s and primary medical literature. UpToDate does not engage in any independent review, testing or
study of	lany medication, medical device, condition, illness, injury test, procedure, treatment, or therapy in
connect	ion with the publication of the content. The content is not intended to explicitly or implicitly endorse any
particula	ar medication as safe or effective for treating any particular patient or health condition.
UpToDa	te assumes no responsibility or lability for errors or omissions of any kind in the content. UpToDate
express	y disclaims any liability for any loss or damage claimed to have resulted from the use of the content.
Users o	the content shall hold UpToDate harmless from any such claims and shall indemity UpToDate for any
expense	is incurred if such claims are made. In no event shall UpToDate be liable to any user or any third-party,
includin	g specifically any customer or patient of a user, for direct, special, indirect, incidental, or consequential
damage	is. UpToDate disclaims all warrantes of any kind or nature, whether expressed or implied, including any
warranty	y as to the quality, accuracy, comprehensiveness, currency, suitability, availability, compatibility,
merchar	natability, and fitness for a particular purpose of the content.

 画面左上のボックスに、薬剤・薬草名を入力します。(半角の英数字でご入力下さい。)
 入力を始めると検索候補が表示されますので、クリックするとボックスの下にある ITEM LIST に追加されます。
 ITEM LIST に追加された薬剤・薬草名をクリックすると、その薬剤と他の薬剤・薬草との飲み合わせ結果一覧が表示 されます。それぞれの結果(緑文字)をクリックすると、詳細な情報が確認していただけます。



4. ITEM LIST に薬剤・薬草を複数入れ、「Analyze」(分析)ボタンをクリックすると、相互作用がある組み合わせとリス ク評価が画面右側に表示されます。分析結果を、前述のように詳細情報(概要や患者管理についてなど)が表示されま

d	
7	0

Lakicomp® Drug Interactions Matterns toy curst it y searching loss TERE IST Car Let Avain Car Let Car Let Avain Car Let Car Let<	opiobate							Lexicomp® Drug Interaction
dd dem to your lan by searching lealow Enter feen name TEER LIST Cear List Caracterial Access SciCAdenia Sc	Lexicomp® Drug Inte	eractions		X Avoid combination	C	Monitor therapy	A No known interaction	
Enter stamme TERE LIST Cere List Orace in List Star List Star List Core relation of the start of the determined of the determine repreded plotted in the bioleconder Listence of the decision, charging information about a drug (e.g. as rel the bioleconder Listence of the information of the decision repreded plotted in the information of the decision of the d	dd items to your list by searching b	elow.		D Consider therapy modificati	ion B I	No action needed	More about Risk Ratings	•
If Beult (Piter Acada U) Or Carl List Awardu SchAdenis SchAdenis Gragethul Luke Complete List of interactions for an individual aser many buck that are finant and the control product information, and changing individual and the function of additional products. Ottable complete List of interactions for an individual aser many buck that are finant and the function of additional products. Functional Complete List of interactions for an individual aser many buck that are finant and the function of additional products. Functional Complete List of interactions for an individual aser many buck that are finant and the function of additional products. Functional Complete List of interactions for an individual aser many buck that are finant and the function of additional products. Functional Complete List of interactions for an individual aser many buck that are finant and the function of additional and the functional complete List of interactions for additional more than the functional and th	Enter item name							
Clear List Charlow Availa Charlow SociAderia Charlow and the decision regarding drop therapy walk be based on the independent judgment of the chickes, charping information stool a drop (eg. es. of the decision regarding drop therapy walk be based on the independent judgment of the chickes, charping information stool a drop (eg. es. of the decision regarding drop therapy walk be based on the independent judgment of the chickes, charping information stool a drop (eg. es. of the decision regarding drop therapy walk be based on the independent judgment of the chickes, charping information stool a drop (eg. es. of the decision regarding drop therapy walk be based on the independent judgment of the chickes, charping information stool a drop (eg. es. of the decision regarding drop therapy walk be based on the independent judgment of the chickes, charping information stool a drop (eg. es. of the decision regarding drop therapy walk be based on the independent judgment of the chickes, charping information stool a drop (eg. es. of the decision regarding drop the decision regroe regarding drop the decision regarding drop the decision regar	ITEM LIST		1 Result				F	ilter Results by Item 👻 Print
Availant Different and availant many advantant many advantant medical status and adva	Clear List	Analyze	C SORAfen Avastin (E	ib Bevacizumab)				
SocAdemo Gradeful Julic Display Control Hele II of Interactions for an individual arm by clicking stem name. This 500 Advents / Hermannese Display represention or administration. To the SofAdvents / Bernacticama Full SofAdvents / Bernacticama F	Avastin		DISCLAIMER: Readers in the literature and ma	s are advised that decisions regarding drug nuncturer's most current product information	therapy must on), and char	be based on the independe ging medical practices.	ent judgment of the clinician, changing inforr	nation about a drug (eg, as reflected
Gradeful Juice Depley complete list of interactions for an individual sem by clicking item name. This tool does not address chemical compatibility Drug Interactions Feedback	SORAfenib							
Chargerful Julie Display Caching Les of interactions for an individual are by clicking item name. This tool does not address chemical compatibility clicking item name. Display Caching Les of an individual are by clicking item name. This tool does not address chemical compatibility clicking item name. Display Caching Les of an individual are by clicking item name. Display Caching Les of an individual are by clicking item name. Display Caching Les of an individual are by clicking item name. Display Caching Les of an individual are by clicking item name. Display Caching Les of a individual are by clicking item name. Display Caching Les of an individual are by clicking item name. Display Caching Les of an individual are by clicking item name. Display Caching Les of an individual are by individual are by individual are by individual are by clicking item name. Display Caching Les of an individual are by clicking item name. Display Caching Les of the development of hand-dot aliverse over nm or by be instanced. Display Caching Les of the development of hand-dot aliverse over nm or by be instanced. Display Caching Les of the development of hand-dot aliverse over nm or by be instanced. Display Caching Les of the development of hand-dot aliverse over nm or by be instanced. Display Ca								
Display camplete list of interactions for an individual tem by clicking item name.	Grapefruit Juice							
Te: This tool does not address chemical compatibility Te: This tool does not address chemical compatibility Drug Interactions E Redback	Display complete list of interaction item by clicking item r	ns for an individual name.						
TE: This tool does not address chemical compatibility Teiled to I.V. dug preparation or administration. Drug Interactions Feedback								
The SORAfenb / Bevacitumata Drug Interactions Feedback)TE: This tool does not address ch	nemical compatibility						
Title SORA/enib / Bevacizumab Risk Rating :: Monitor therapy Summary Brovacizumab may enhance the adverse/hole effect of SORA/enib. Specifically, the risk for hand-foot shin reaction may be increased. Severity Modernie Ratiability Rating Good Patient Management Monitor patients closely for the development of hand-foot shin reaction (HFSR) during containation therapy with soraferib and bevacizumab as the incidence and severity of this adverse event may be provide (grade (grade) starter when Socialers hole Summary ende (grade) Summary ende (grade) Summary ende (grade) Summary ende (grade) Summary ende (grade) Footnotes など Footnotes など 1. Azed NS, Aregon-Ching JB, Dahut VIL, et al. Hand-foot shin reaction increases with cumulative socialities 1. Azed NS, Aregon-Ching JB, Dahut VIL, et al. Hand-foot shin reaction increases with cumulative social 1. Azed NS, Aregon-Ching JB, Dahut VIL, et al. Hand-foot shin reaction increases with cumulative social 1. Azed NS, Aregon-Ching JB, Dahut VIL, et al. Hand-foot shin reaction increases with cumulative social 1. Azed NS, Aregon-Ching JB, Dahut VIL, et al. Hand-foot shin reaction increases with cumulative social starts in the combination and indexecular endothelial growth factor therapy. <i>Clin Cancer Res.</i> 2009; 15(4):14 1. Oneen EG, Perking SM, Strother RM, et al. Phase L, pharmacogenomic, drug-interaction study of social	Drug Interactions Fee	dback						
Title SORA/enib / Bevacizumab Pert Risk Rating C: Monitor therapy Pert Summary Bevacizumab may enhance the adverse/toxic effect of SORA/enib. Specifically, the risk for hand-foot skin reaction may be increased. Severity Moderate Reliability Rating Good Patient Management Monitor patients closely for the development of hand-foot skin reaction (HFSR) during common with sorafenib and bevacizumab as the incidence and severity of file adverse event may be greater with sorafenib and bevacizumab as the incidence and severity of file adverse event may be greater with sorafenib and bevacizumab as the incidence and severity of file adverse event may be greater with sorafenib paties and bevacizumab as the incidence and severity of file adverse event may be greater with greater adverse the incidence and severity of file adverse event may be greater with sorafenib paties. Discussion greater with greater adverse for the development of hand-foot skin reaction (HFSR) during common with greater adverse event may be greater with greater adverse event may be greater adverse adverse adverse event may be greater adv								
Title SORAfenib / Bevacizumab put Risk Rating C: Monitor therapy put Summary Bevacizumab may enhance the adverse/solve affect of SORAfenib. Specifically, the risk for hand-foot sin reaction may be increased. Severity Moderate Reliability Rating Good Puter Management Monitor patients closely for the development of hand-foot skin reaction (HSR) during condition therapy with sorafenib and bevacizumab as the incidence and severity of this adverse event may be increased. Severity Moderate Reliability Rating Good Riscussion								
Title SORAtenib / Bevacizumab Pase Risk Rating C: Monitor therapy Summary Bevacizumab may enhance the adverse/toxic effect of SORAfenib. Specifically, the risk for hand-foot skin reaction may be increased. Severity Moderate Reliability Rating Good Patient Management Monitor patients closely for the development of hand-foot skin reaction underseave the incidence and severity of this adverse event may be greater when sonafenib and bevacizumab as the incidence and severity of this adverse event may be greater when event the sonafenib and bevacizumab as the incidence and severity of this adverse event may be greater when event the sonafenib and bevacizumab as the incidence and severity of this adverse event may be greater when event the sonafenib and bevacizumab as the incidence and severity of this adverse event may be greater when event the sonafenib and bevacizumab as the incidence and severity of this adverse event may be greater when event the sonafenib and bevacizumab as the incidence and severity of this adverse event may be greater when event the sonafenib of the greater when event the sonafenib of the sonafenib								
summary Bevacicumab may enhance the adverse#toxic effect of SORAfenib. Specifically, the risk for hand-foot skin reaction may be increased. Severity Moderate Reliability Rating Good Patient Management Monitor patients closely for the development of hand-foot skin reaction (HFSR) during combination thereave with sorafenib and bevacicumab as the incidence and severity of this adverse event may be greater when Discussion screifenib prize Summary and (grede study of patie HrSR was st The mechania VGGF vaccu. Bottome The Monitor Statistic Monitor Statisti	-					-		
SMI relation that be the detailed.executing inducting	TILL	le SORAfenib / Bevacizum	iab	•	Prie			
combination therapy with sordernib and boyacizamab as the incidence and severity of this adverse over the my be greater when Discussion sorafemib plus common with grade (grade study of patie HFSR was size The mechania VEGF vascul Kinase inhibit may be respon- Footnotes など 1. Azad NS, Aragon-Ching JB, Dehut WL, et al. Hand-foot skin reaction increases with cumulative sorafemib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clin Cancer Res.</i> 2009;15(4):141 1161. [PubMed 19228742] 2. Chiorean EG, Perkins SM, Strother RM, et al. Phase I, pharmacogenomic, drug-interaction study of soraf	Titi Ris Sur	e SORAfenib / Bevacizum ik Rating C: Monitor thera mmary Bevacizumab may	iab py renhance the adverse/loxic	effect of SORAtenib. Specifically, the ris	Prin sk for hand-fi	: pot		
biscussion A scrafenib pite surgering (grade study of patie study of patie HFSR was sit The mechania VEGF (vascs) The me	Titk Ris Sur skin Pat	e SORAfenib / Bevacizum k Rating C: Monitor thera mmary Bevacizumab may reaction may be increas- tient Management Monito	nab PY en hance the adverse/toxic cd. Severity Moderate Relia r patients closely for the dev	effect of SORAfenib. Specifically, the ris bility Rating Good	Prin sk for hand-fi FSR) during	: bot		
common with grade (grade study of patie HFSR was sit The mechanic VEGF (vacout kinase inhibit may be respon Footnotes 1. Azad NS, Aragon-Ching JB, Dehut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clin Cancer Res.</i> 2009;15(4):14 1416. FleyMedbal 19228742 2. Chiorean EG, Perkins SM, Strother RM, et al. Phase I, pharmacogenomic, drug-interaction study of soraf	Titi Ris Sur skin Pat or gree	e SORAfenib / Bevacizum k Rating C: Monitor thera manay Bevacizumab may n reaction may be increase sient Management Monitor hination therapy with som ater when	hab py renhance the adverse/toxic ed. Severity Moderate Relia r patients closely for the dev afenib and bevacizumab as in $\Delta = \Delta + L + \Delta = \Xi^{+} \langle m = 2 \rangle$	effect of SORAfenib. Specifically, the ris billity Rating Good velopment of hand-foot skin reaction (HF the incidence and severity of this adverse	Prin Sk for hand-fi FSR) during se ovent ma	r bot		
HFSR was st The mechanic VECF Viscol Name inhibit may be reactor Footnotes など 1. Azd N3, Aregon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative soratenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clin Cancer Res.</i> 2009;15(4):141 1161. [PubMed 19228742] 2. Chlorean EG, Perkins SM, Strother RM, et al. Phase I, pharmacogenomic, drug-interaction study of sorat	Titi Ris Sur skin Pat con gree Dis sor	e SORAfenib / Bevacizum ik Rating C: Monitor there mmary Bevacizumab may reaction may be increase tient Management Monitor handom threator with sor- ator when cussion brus ator brus	hab Py enhance the adverse/toxic ed. Severity Moderate Relia r/ patients closely for the dev afenib and bevadzumeb as 合わせの詳細:	effect of SORAfenib. Specifically, the ris billty Rating Good velopment of hand-toot skin reaction (HH the incidence and severity of this adverse	Pier Sk for hand-fi FSR) during se event mar and 1 study web more	sot z be f		
The mechania VEGF vascul kinase inhibit may be respon Footnotes など 1. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clin Cancer Res.</i> 2009;15(4):141 1161. [PubMed 19228742] 2. Chiorean EG, Perkins SM, Storther RM, et al. Phase I, pharmacogenomic, drug-interaction study of soraf	Titi Ris Sun skin Pat con gree pro con gree pro con gree	e SORAfenib / Bevacizum k Rating C: Monitor there mmary Bevacizumab may reaction may be increase internation therapy with sor atter when crussion A ないのか 能 ののの 能 していたいです。 していで	nab Py renhance the adverse/toxic ed Severity Modernet Relia genie and bevadizumate as 含わせの詳細: Summary Pationt Ma	effect of SORAfenib. Specifically, the ris bitity Rating Good velopment of hand-loot skin reaction (HF he incidence and severity of this adverse	Print Sk for hand-fi FSR) during se event mar event mare for 1 study means of 1 study means of 1 study means of 1 study	r be r be r r		
kindse inhibite may be respo Footnotes 1. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative soratenib dose and with combination arti-vascular endothelial growth factor therapy. <i>Clin Cancer Res.</i> 2009;15(4):14 1116. [PubMed 19228742] 2. Chiorean EG, Perkins SM, Strother RM, et al. Phase I, phermacogenomic, drug-interaction study of soret	Titi Ris Sur skir Pat con grea sorr graa graa graa strikt	e SORAfenib / Bevacizum k Rating C: Monitor there mmary Bevacizumab may n reaction may be increase ient Management Monito mbination therapy with son ater when cursaion a fernib put a faring put a faring put a faring put son son son son son son son son son son	ab py renhance the adverse/toxic ed. Severity Mcderate Relia r patients closely for the dev afanib and bevacizumab as 合わせの詳細: Summary Patient Ma Discussion	effect of SORAfenib. Specifically, the ris bility Rating Good velopment of hand-foot skin reaction (HF the incidence and severity of this adversed nagement	Print Sk for hand-fi FSR) during se event mar event mare dense event se event mar dense event se event mar dense event se event s	oot y be f er de		
Footnotes 1. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anth-vascular endothelial growth factor therapy. <i>Clin Cancer Res.</i> 2009;15(4):141 1416. FlyzModul 19228742 2. Chiorean EG, Perkins SM, Strother RM, et al. Phase I, pharmacogenomic, drug-interaction study of soraf 2. Chiorean EG, Perkins SM, Strother RM, et al. Phase I, pharmacogenomic, drug-interaction study of soraf	Titi Ris Suu skir Pat con gree Dis score con gree store store store the Store The VEC	e SORAfenib / Bevacizum k Rating C: Monitor thera mmany Bevacizumab may n reaction may be increase lient Management Monitor ater when faction brazer with som ater when faction brazer factor brazer ater when factor brazer factor brazer	nab py renhance the adverse/toxic ed. Severity Moderate Relia r patients closely for the dev afenib and bevacizumab as 合わせの詳細: Summary Patient Ma Discussion Footnotes	effect of SORAfenib. Specifically, the ris billity Rating Good webprent of hand-foot skin reaction (HF the incidence and severity of this adversed nagement	Print Sk for hand-fi FSR) during So overf mar over trace dense of high so i in enther here of all gr opechally y 2 due in botho	r be r be rf rer de		
1. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-doxt skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):141 1416. [PubMed 19228742] 2. Chiorean EG, Perkins SM, Strother RM, et al. Phase I, pharmacogenomic, drug-interaction study of sorat	Titi Ris Sun skir Pat con gree gree bis sore con grea tut tut The VEck kinding	e SORAfenib / Bevacizum k Rating C: Monitor there mmary Bevacizumab may r reaction may be increase tient Management Monito ater when hoccussion a ater when hoccussion a group ater of of pate SR was sig are mechania of r (vacut one inhibit; be respondent of context of context	ab py renhance the adverse/toxic ed. Severity Moderate Relia r patients closely for the dev admb and bevacizumate as 合わせの詳細: Summary Patient Ma Discussion Footnotes	effect of SORAfenib. Specifically, the ris billity Rating Good velopment of hand-foot skin reaction (HF the incidence and severity of this advers nagement など	Pre sk for hand-fi FSR) during se event mar se event mar	sot be f er de of 7		
1010. [Eventsed Location] 2. Chlorean EG, Perkins SM, Strother RM, et al. Phase I, pharmacogenomic, drug-interaction study of sore	Titi Ris Sur skir Pat con gree Dis sor con gree the HSF HT HF VEC kir htt For Pot	e SORAfenib / Bevacizum ak Rating C: Monitor there mmary Bevacizumab may reaction may be increase tient Management Monitor teator when ccussion b ator when ccussion b ator when course of the second of grade of grade arechania GF (vacuuma teator) to the second of the second	ab py renhance the adverse/toxic ed. Severity Moderate Relia r patients closely for the dev adrab and bevacizement as 合わせの詳細: Summary Patient Ma Discussion Footnotes	effect of SORAfenib. Specifically, the ris billity Rating Good velopment of hand-foot skin reaction (HH the incidence and severity of this adverse nagement など	Pre- sk for hand-fi FSR) during so overt ma and 1 state dense reference dense of the dense reference dense ref	sot be if ier de of F)		
	Titi Ris Sun skir Pat con gre Dis sor con gra stuc HFS The VEC kinn may Foo Con 1. A dos	e SORAfenib / Bevacizum k Rating C: Monitor there mmary Bevacizumab may reaction may be increase tient Management Monito interator with sort afenib plus afenib affenib afenib affenib affenib afenib affen	nab Py renhance the adverse/toxic. ed Severity Moderate Relia arpatients closely for the dev afanib and bevacizomab as 合わせの詳細: Summary Patient Ma Discussion Footnotes a, Dahut WL, et al. Hand-foo rtl-vascular endothelial grow	effect of SORAfenib. Specifically, the ris bility Rating Good webprent of hand-foot skin reaction (HF the incidence and severity of this adverse nagement など	Print Sk for hand-fi FSR) during so overt mar over the source of the source of the sou	toot t be of de of T		
and bevacizumab in combination with pacilitaxel in patients with advanced refractory solid tumors [published online August 26, 2020]. Mol Cancer Ther. Doi: 10.1158/1535-7163.MCT-20-0277. [Publied 32847973]	Titi Ris Su ski Pat con gre Dis sors con gran stu HES The VE kine may Foc 1.A dos 141.2	le SORAfenib / Bevacizum ik Rating C: Monitor thera mmary Bevacizumab may neaction may be increase isent Management Monitor mater when a famib plus a mechanis SR was sig a mechanis SR was sig a mechanis SR was sig a mechanis SR was sig a mechanis Be respo stortese txad NS, Aragon-Ching JE ise and with combination a I (bubMed 192287) 421 Chiorean EG, Perkins SM,	nab Py renhance the adverse/toxic ed. Severity Moderate Relia rentation and bevacizumab as in 合わせの詳細: Summary Patient Ma Discussion Footnotes a, Dahut WL, et al. Hand-foo nti-vascular endothelial grow	effect of SORAfenib. Specifically, the ris bility Rating Good velopment of hand-foot skin reaction (HF he incidence and severity of this adverse nagement など t skin reaction increases with cumulative th factor therapy. <i>Clin Cancer Res.</i> 2009 phermacogenomic, drug-interaction stu	Pre- sk for hand-fi FSR) during se event mar- dense of the second of the	で of of つ 可 可 更にここか	ら PubMed に飛び	び、参照リファレ